264 related articles for article (PubMed ID: 25437562)
1. Structure and cancer immunotherapy of the B7 family member B7x.
Jeon H; Vigdorovich V; Garrett-Thomson SC; Janakiram M; Ramagopal UA; Abadi YM; Lee JS; Scandiuzzi L; Ohaegbulam KC; Chinai JM; Zhao R; Yao Y; Mao Y; Sparano JA; Almo SC; Zang X
Cell Rep; 2014 Nov; 9(3):1089-98. PubMed ID: 25437562
[TBL] [Abstract][Full Text] [Related]
2. Host b7x promotes pulmonary metastasis of breast cancer.
Abadi YM; Jeon H; Ohaegbulam KC; Scandiuzzi L; Ghosh K; Hofmeyer KA; Lee JS; Ray A; Gravekamp C; Zang X
J Immunol; 2013 Apr; 190(7):3806-14. PubMed ID: 23455497
[TBL] [Abstract][Full Text] [Related]
3. The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3.
Janakiram M; Shah UA; Liu W; Zhao A; Schoenberg MP; Zang X
Immunol Rev; 2017 Mar; 276(1):26-39. PubMed ID: 28258693
[TBL] [Abstract][Full Text] [Related]
4. The B7x Immune Checkpoint Pathway: From Discovery to Clinical Trial.
John P; Wei Y; Liu W; Du M; Guan F; Zang X
Trends Pharmacol Sci; 2019 Nov; 40(11):883-896. PubMed ID: 31677920
[TBL] [Abstract][Full Text] [Related]
5. Potential targeting of B7-H4 for the treatment of cancer.
Podojil JR; Miller SD
Immunol Rev; 2017 Mar; 276(1):40-51. PubMed ID: 28258701
[TBL] [Abstract][Full Text] [Related]
6. Co-inhibitory Molecule B7 Superfamily Member 1 Expressed by Tumor-Infiltrating Myeloid Cells Induces Dysfunction of Anti-tumor CD8
Li J; Lee Y; Li Y; Jiang Y; Lu H; Zang W; Zhao X; Liu L; Chen Y; Tan H; Yang Z; Zhang MQ; Mak TW; Ni L; Dong C
Immunity; 2018 Apr; 48(4):773-786.e5. PubMed ID: 29625896
[TBL] [Abstract][Full Text] [Related]
7. B7 immune-checkpoints as targets for the treatment of neuroendocrine tumors.
Yuan Z; Gardiner JC; Maggi EC; Huang S; Adem A; Bagdasarov S; Li G; Lee S; Slegowski D; Exarchakis A; Howe JR; Lattime EC; Zang X; Libutti SK
Endocr Relat Cancer; 2021 Feb; 28(2):135-149. PubMed ID: 33410766
[TBL] [Abstract][Full Text] [Related]
8. B7-H4(B7x)-Mediated Cross-talk between Glioma-Initiating Cells and Macrophages via the IL6/JAK/STAT3 Pathway Lead to Poor Prognosis in Glioma Patients.
Yao Y; Ye H; Qi Z; Mo L; Yue Q; Baral A; Hoon DSB; Vera JC; Heiss JD; Chen CC; Zhang J; Jin K; Wang Y; Zang X; Mao Y; Zhou L
Clin Cancer Res; 2016 Jun; 22(11):2778-2790. PubMed ID: 27001312
[TBL] [Abstract][Full Text] [Related]
9. Development of a novel anti-B7-H4 antibody enhances anti-tumor immune response of human T cells.
Miao G; Sun X
Biomed Pharmacother; 2021 Sep; 141():111913. PubMed ID: 34328096
[TBL] [Abstract][Full Text] [Related]
10. Induced expression of B7-H4 on the surface of lung cancer cell by the tumor-associated macrophages: a potential mechanism of immune escape.
Chen C; Qu QX; Shen Y; Mu CY; Zhu YB; Zhang XG; Huang JA
Cancer Lett; 2012 Apr; 317(1):99-105. PubMed ID: 22108530
[TBL] [Abstract][Full Text] [Related]
11. B7x-from bench to bedside.
Kaur G; Janakiram M
ESMO Open; 2019; 4(5):e000554. PubMed ID: 31555486
[TBL] [Abstract][Full Text] [Related]
12. B7x/B7-H4 modulates the adaptive immune response and ameliorates renal injury in antibody-mediated nephritis.
Pawar RD; Goilav B; Xia Y; Herlitz L; Doerner J; Chalmers S; Ghosh K; Zang X; Putterman C
Clin Exp Immunol; 2015 Feb; 179(2):329-43. PubMed ID: 25205493
[TBL] [Abstract][Full Text] [Related]
13. A SOX9-B7x axis safeguards dedifferentiated tumor cells from immune surveillance to drive breast cancer progression.
Liu Y; John P; Nishitani K; Cui J; Nishimura CD; Christin JR; Couturier N; Ren X; Wei Y; Pulanco MC; Galbo PM; Zhang X; Fu W; Cui W; Bartholdy BA; Zheng D; Lauvau G; Fineberg SA; Oktay MH; Zang X; Guo W
Dev Cell; 2023 Dec; 58(23):2700-2717.e12. PubMed ID: 37963469
[TBL] [Abstract][Full Text] [Related]
14. Preparation and characterization of monoclonal antibody against human B7-H4 molecule.
Zhang N; Fang P; Gu ZJ
Monoclon Antib Immunodiagn Immunother; 2014 Aug; 33(4):270-4. PubMed ID: 25171007
[TBL] [Abstract][Full Text] [Related]
15. Unstable B7-H4 cell surface expression and T-cell redirection as a means of cancer therapy.
Iizuka A; Kondou R; Nonomura C; Ashizawa T; Ohshima K; Kusuhara M; Isaka M; Ohde Y; Yamaguchi K; Akiyama Y
Oncol Rep; 2016 Nov; 36(5):2625-2632. PubMed ID: 27632942
[TBL] [Abstract][Full Text] [Related]
16. Novel recombinant human b7-h4 antibodies overcome tumoral immune escape to potentiate T-cell antitumor responses.
Dangaj D; Lanitis E; Zhao A; Joshi S; Cheng Y; Sandaltzopoulos R; Ra HJ; Danet-Desnoyers G; Powell DJ; Scholler N
Cancer Res; 2013 Aug; 73(15):4820-9. PubMed ID: 23722540
[TBL] [Abstract][Full Text] [Related]
17. Synergistic effects of host B7-H4 deficiency and gemcitabine treatment on tumor regression and anti-tumor T cell immunity in a mouse model.
Leung J; St-Onge P; Stagg J; Suh WK
Cancer Immunol Immunother; 2017 Apr; 66(4):491-502. PubMed ID: 28074226
[TBL] [Abstract][Full Text] [Related]
18. Tissue-expressed B7x affects the immune response to and outcome of lethal pulmonary infection.
Hofmeyer KA; Scandiuzzi L; Ghosh K; Pirofski LA; Zang X
J Immunol; 2012 Sep; 189(6):3054-63. PubMed ID: 22855708
[TBL] [Abstract][Full Text] [Related]
19. New checkpoints in cancer immunotherapy.
Ni L; Dong C
Immunol Rev; 2017 Mar; 276(1):52-65. PubMed ID: 28258699
[TBL] [Abstract][Full Text] [Related]
20. Checkpoint regulator B7x is epigenetically regulated by HDAC3 and mediates resistance to HDAC inhibitors by reprogramming the tumor immune environment in colorectal cancer.
Li Y; Liu Y; Zhao N; Yang X; Li Y; Zhai F; Zang X; Cui W
Cell Death Dis; 2020 Sep; 11(9):753. PubMed ID: 32934224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
